ZNTL Zentalis Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1725160 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-33.8%
TTM net income YoY16.7%
TTM EPS YoY16.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-615.2%
Net margin-555.8%
FCF margin-498.8%
EBITDA margin-611.8%
Returns
ROE-49.2%
ROA-38.4%
ROIC (approx.)-49.6%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets22.7%
Debt / equity0.00x
Current ratio7.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-3.9%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $0 | $0 | $0 | $0 | $26.86M |
| R&D expense | $22.33M | $35.16M | $28.72M | $29.49M | $22.95M | $27.61M | $27.25M | $32.97M |
| SG&A expense | $8.82M | $9.23M | $9.14M | $7.91M | $10.78M | $8.45M | $10.58M | $40.01M |
| Operating income | -$31.15M | -$44.39M | -$37.85M | -$37.39M | -$33.73M | -$36.06M | -$45.62M | -$49.85M |
| Pretax income | -$28.70M | -$42.15M | -$35.23M | -$34.77M | -$26.69M | -$26.87M | -$48.28M | -$47.68M |
| Income tax | $118,000 | $138,000 | $120,000 | $442,000 | $0 | $0 | $0 | -$205,000 |
| Net income | -$28.82M | -$42.29M | -$35.35M | -$35.22M | -$26.69M | -$26.87M | -$48.28M | -$47.47M |
| EBITDA | -$31.00M | -$44.24M | -$37.70M | -$37.24M | -$33.57M | -$35.90M | -$45.36M | -$49.53M |
| EPS (basic) | -0.34 | -0.59 | -0.50 | — | -0.37 | -0.37 | -0.67 | — |
| EPS (diluted) | -0.34 | -0.59 | -0.50 | — | -0.37 | -0.37 | -0.67 | — |
| Weighted avg. shares (diluted) | 84.61M | 71.33M | 70.26M | — | 72.14M | 71.99M | 71.68M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $24.03M | $24.78M | $31.93M | $35.99M | $39.07M | $37.60M | $41.93M | $36.53M |
| Short-term investments | $204.86M | $149.82M | $179.83M | $209.90M | $239.22M | $249.04M | $278.37M | $318.01M |
| Receivables | — | — | — | $0 | $0 | $0 | $0 | $5.00M |
| Current assets | $237.27M | $181.28M | $218.10M | $253.19M | $288.30M | $311.60M | $342.88M | $386.07M |
| PP&E, net | $2.35M | $2.50M | $2.65M | $2.77M | $2.93M | $3.09M | $3.25M | $4.70M |
| Goodwill | — | — | — | — | — | — | — | $0 |
| Total assets | $270.19M | $215.33M | $253.07M | $288.97M | $327.25M | $351.71M | $384.02M | $430.34M |
| Current liabilities | $32.36M | $37.63M | $35.24M | $36.56M | $37.17M | $39.02M | $49.43M | $52.73M |
| Total liabilities | $65.31M | $71.68M | $70.39M | $72.76M | $74.38M | $77.21M | $88.64M | $93.15M |
| Shareholders' equity | $204.89M | $143.65M | $182.68M | $216.20M | $252.87M | $274.50M | $295.38M | $337.19M |
| Shares outstanding | 98.26M | 71.67M | 71.16M | 69.09M | 72.25M | 72.14M | 71.95M | 71.28M |
| Cash flow statement | ||||||||
| Operating cash flow | -$32.71M | -$37.24M | -$32.96M | -$30.94M | -$26.96M | -$34.71M | -$32.64M | -$39.70M |
| Capital expenditure | $0 | $0 | $34,000 | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | -$32.71M | -$37.24M | -$32.99M | -$30.94M | -$26.96M | -$34.71M | -$32.64M | -$39.70M |
| Investing cash flow | -$55.31M | $30.02M | $30.01M | $32.45M | $28.32M | $30.38M | $40.48M | $32.28M |
| Financing cash flow | $87.26M | $65,000 | -$1.12M | -$4.59M | $115,000 | $0 | $189,000 | $0 |
| Depreciation & amortization | $152,000 | $152,000 | $151,000 | $157,000 | $160,000 | $160,000 | $262,000 | $317,000 |
| Stock-based compensation | $3.21M | $3.21M | $3.20M | $3.12M | $4.83M | $6.29M | $6.49M | $31.36M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.